Find Vibegron manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1190389-15-1, Krp-114v, Gemtesa, Mk-4618, (s)-n-(4-(((2s,5r)-5-((r)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide, M5tse03w5u
Molecular Formula
C26H28N4O3
Molecular Weight
444.5  g/mol
InChI Key
DJXRIQMCROIRCZ-XOEOCAAJSA-N
FDA UNII
M5TSE03W5U

Vibegron
Vibegron is a potent, selective beta-3 adrenergic receptor (3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder, a condition associated with distressing symptoms of urge urinary incontinence, urgency, and urinary frequency, and reduced quality of life of patients. On December 23, 2020, vibegron was approved for the same indication in adults. It is available as oral tablets under the market name GEMTESA. Vibegron is the second beta-3 adrenergic agonist approved for the treatment of overactive bladder following [mirabegron], which was approved in 2012. Unlike mirabegron, vibegron is less likely to be associated with drug-drug interactions involving the CYP3A4, 2D6, or 2C9 enzymes.
1 2D Structure

Vibegron

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(6S)-N-[4-[[(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6H-pyrrolo[1,2-a]pyrimidine-6-carboxamide
2.1.2 InChI
InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1
2.1.3 InChI Key
DJXRIQMCROIRCZ-XOEOCAAJSA-N
2.1.4 Canonical SMILES
C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O
2.1.5 Isomeric SMILES
C1C[C@@H](N[C@@H]1CC2=CC=C(C=C2)NC(=O)[C@@H]3CCC4=NC=CC(=O)N34)[C@@H](C5=CC=CC=C5)O
2.2 Other Identifiers
2.2.1 UNII
M5TSE03W5U
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Mk-4618

2. N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide

2.3.2 Depositor-Supplied Synonyms

1. 1190389-15-1

2. Krp-114v

3. Gemtesa

4. Mk-4618

5. (s)-n-(4-(((2s,5r)-5-((r)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide

6. M5tse03w5u

7. C26h28n4o3

8. Mk4618

9. (6s)-n-(4-(((2s,5r)-5-((r)-hydroxyphenylmethyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide

10. Pyrrolo(1,2-a)pyrimidine-6-carboxamide, 4,6,7,8-tetrahydro-n-(4-(((2s,5r)-5-((r)-hydroxyphenylmethyl)-2-pyrrolidinyl)methyl)phenyl)-4-oxo-, (6s)-

11. Beova

12. Pyrrolo[1,2-a]pyrimidine-6-carboxamide, 4,6,7,8-tetrahydro-n-[4-[[(2s,5r)-5-[(r)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxo-, (6s)-

13. Vibegron [usan]

14. Vibegron [usan:inn]

15. Unii-m5tse03w5u

16. Vibegronum

17. Beova (tn)

18. Mk 4618

19. Vibegron (jan/usan)

20. Vibegron [inn]

21. Vibegron [jan]

22. Vibegron [who-dd]

23. Vibegron [orange Book]

24. Chembl2107826

25. Schembl11985457

26. Gtpl10100

27. Dtxsid40152299

28. Chebi:142418

29. Ex-a3390

30. Bdbm50146154

31. Mfcd28502057

32. At23148

33. Compound 7 [pmid: 26709102]

34. Db14895

35. Hy-19933

36. Cs-0016926

37. D10433

38. A903957

39. Q27283524

40. (6s)-4,6,7,8-tetrahydro-n-[4-[[(2s,5r)-5-[(r)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxo-pyrrolo[1,2-a]pyrimidine-6-carboxamide

41. (6s)-4,6,7,8-tetrahydro-n-[4-[[(2s,5r)-5-[(r)-hydroxyphenylmethyl]-2-pyrrolidinyl]methyl]phenyl]-4-oxopyrrolo[1,2-a]pyrimidine-6-carboxamide

42. (6s)-n-(4-(((2s,5r)-5-((r)-hydroxy(phenyl)methyl)pyrrolidin-2-yl(methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-

43. (6s)-n-[4-({(2s,5r)-5-[(r)-hydroxy(phenyl)methyl]pyrrolidin-2-yl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxamide

44. (6s)-n-[4-[[(2s,5r)-5-[(r)-hydroxy(phenyl)methyl]pyrrolidin-2-yl]methyl]phenyl]-4-oxo-7,8-dihydro-6h-pyrrolo[1,2-a]pyrimidine-6-carboxamide

2.4 Create Date
2009-11-30
3 Chemical and Physical Properties
Molecular Weight 444.5 g/mol
Molecular Formula C26H28N4O3
XLogP31.8
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count6
Exact Mass444.21614077 g/mol
Monoisotopic Mass444.21614077 g/mol
Topological Polar Surface Area94 Ų
Heavy Atom Count33
Formal Charge0
Complexity782
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Vibegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Vibegron selectivity for beta-3 adrenergic receptors is >9000 times higher than for 1AR or 2AR. Vibegron improves clinical symptoms of overactive bladder by increasing bladder capacity without affecting bladder contraction. It significantly increases the functional bladder volume in a dose-dependent manner, which results in prolongation of the interval between voids. In clinical studies, vibegron inhibited detrusor bladder contractions in a concentration-dependent manner, reduced voiding pressure, and increased bladder compliance. In Japanese clinical studies comprising patients with overactive bladder, vibegron significantly improved the frequency of micturition, urgency, and urgency incontinence episodes.


5.2 Absorption, Distribution and Excretion

Absorption

The mean Tmax is 1-3 hours. Steady-state concentrations are achieved within 7 days of once-daily dosing.


Route of Elimination

In a radiolabeled drug study, approximately 59% of the radiolabeled dose was recovered in feces, in which 54% of that amount was in the unchanged parent drug form. About 20% of the radioactivity was recovered in urine, in which 19% of the amount was in the unchanged form.


Volume of Distribution

The mean apparent volume of distribution is 6304 L. The average blood-to-plasma concentration ratio is 0.9. According to tissue distribution studies in animals, vibegron does not penetrate the blood-brain barrier, suggesting limited potential for CNS toxicity in humans.


Clearance

There is limited information on the clearance rate of vibegron.


5.3 Metabolism/Metabolites

In vitro, CYP3A4 is the main enzyme responsible for the metabolism of vibegron, which plays a minor role in the elimination of vibegron. Two predominant metabolic pathways are oxidation and glucuronidation to form two oxidative metabolites and three glucuronide metabolites. Metabolites have not been fully characterized.


5.4 Biological Half-Life

The terminal plasma half-life ranges from 60 to 70 hours. The effective half-life is 30.8 hours.


5.5 Mechanism of Action

Overactive bladder is characterized by symptoms of urge urinary incontinence, urgency, and urinary frequency. Bladder filling and emptying are regulated by the coordinated communication between sympathetic and parasympathetic systems. Bladder filling occurs via parasympathetic inhibition and the sympathetic hypogastric nerve releasing norepinephrine, which acts on beta-adrenergic receptors responsible for mediating detrusor muscle relaxation. Symptoms of overactive bladder are thought to be caused by the deterioration of the sensory connections between the bladder, spinal cord and brain, leading to changes in the lower urinary tract and abnormal bladder sensations of the urge to void at small bladder volumes. Beta-3 adrenergic receptors (3ARs) are expressed in the kidneys and lower urinary tract, including ureters, urethra, prostate, and bladder. Vibegron is a selective agonist at 3AR. One vibegron binds to the receptor, 3AR is stimulated and undergoes a conformation change and activates adenylyl cyclases (AC), which promotes the formation of cyclic adenosine monophosphate (cAMP). Increased intracellular cAMP concentration leads to the activation of cAMP-dependent protein kinase A (PKA), which subsequently phosphorylates myosin light chains that are responsible for inhibiting the interaction of actin with myosin dependent on calcium calmodulin complex. In clinical trials, vibegron increased cAMP levels in a dose-proportional manner. There is evidence that 3AR agonists may also work via sensory mechanisms without directly affecting detrusor muscle motor function.


API SUPPLIERS

read-more
read-more

01

Porton Pharma Solutions

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPorton Pharma Solutions: Value creation via innovation & discovery through technical platforms.

Flag China
Digital Content Digital Content
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Porton Company Banner

02

Ami Lifesciences Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAMI Lifesciences is Driven by Chemistry. Powered by People.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF arrow-down VMF Others AUDIT
AMI Lifesciences

03

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Metrochem

04

Suanfarma

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSuanfarma, at the Core of a Better Life.

Flag Spain
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Suanfarma

05

Medichem S.A

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMedichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.

Flag Spain
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Medichem

06

HONOUR LAB LTD

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

HONOUR LAB LTD

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Aurisco Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

Aurisco Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Duphat
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Shanghai Hope Chem

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

09

Symed Labs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow

10

Beijing Sjar Technology Developmen...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Duphat
Not Confirmed
arrow
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

Duphat
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPorton Pharma Solutions: Value creation via innovation & discovery through technical platforms.

Flag China
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 40275

Submission : 2024-08-01

Status : Active

Type : II

Porton Company Banner

02

Duphat
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAMI Lifesciences is Driven by Chemistry. Powered by People.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2024-07-31

Pay. Date : 2024-06-13

DMF Number : 39538

Submission : 2024-03-21

Status : Active

Type : II

AMI Lifesciences

03

Duphat
Not Confirmed

03

Duphat
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-08-16

Pay. Date : 2024-07-19

DMF Number : 40068

Submission : 2024-07-14

Status : Active

Type : II

blank

04

Honour Lab Ltd

India

USDMF

arrow
Duphat
Not Confirmed

04

Duphat
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-11-12

Pay. Date : 2024-09-24

DMF Number : 40333

Submission : 2024-09-27

Status : Active

Type : II

blank

05

Msn Organics Private Ltd

Country

USDMF

arrow
Duphat
Not Confirmed

05

Msn Organics Private Ltd

Country
arrow
Duphat
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-10-22

Pay. Date : 2024-09-26

DMF Number : 40304

Submission : 2024-09-24

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-more

01

arrow
BIO Partnering at JPM
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAMI Lifesciences is Driven by Chemistry. Powered by People.

Flag India
Digital Content Digital Content

Vibegron

Registrant Name : Aging Life Science Co., Ltd.

Registration Date : 2024-11-07

Registration Number : 434-69-ND

Manufacturer Name : Ami Lifesciences Private Lim...

Manufacturer Address : Block No. 82/B, ECP Road At & Post. Karakhadi, Tal-Padra, City : Karakhadi – 391 45...

AMI Lifesciences

02

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Vibegron

Registrant Name : Jeil Pharmaceutical Co., Ltd.

Registration Date : 2022-10-31

Registration Number : Su216-24-ND

Manufacturer Name : Sumitomo Chemicals Co., Ltd....

Manufacturer Address : 3750, Azajuhachicho, Maki, Ampachicho, Ampachi-Gun, Gifu 503-0125, Japan

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

arrow
Biotech Showcase
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPorton Pharma Solutions: Value creation via innovation & discovery through technical platforms.

Flag China
Digital Content Digital Content

Vibegron

About the Company : Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & operation facilities ar...

Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & operation facilities are located in China, Slovenia, the US, Belgium, Switzerland, Denmark, with more than 6000 employees worldwide. Porton leads the way with its excellent CDMO services, but also supplies APIs & intermediates for the treatment of critical diseases such as HIV/AIDS, diabetes, cancer, & influenza. Our Process Technology Centers & WHO/USFDA/EMA/PDMA/NMPA-inspected Facilities feature state-of-the-art equipment, highly flexible cGMP-compliant production assets.
Porton Company Banner

02

arrow
Biotech Showcase
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAMI Lifesciences is Driven by Chemistry. Powered by People.

Flag India
Digital Content Digital Content

Vibegron

About the Company : Ami Lifesciences, established in 2006, is one of the fastest growing API manufacturing companies in India. Specializing in cardiovascular, anti-diabetic, CNS, and respiratory thera...

Ami Lifesciences, established in 2006, is one of the fastest growing API manufacturing companies in India. Specializing in cardiovascular, anti-diabetic, CNS, and respiratory therapeutic areas, Ami offers a wide range of APIs, intermediates, key starting materials, as well as contract bulk manufacturing services. Ami's manufacturing units in Gujarat and Karnataka feature dedicated clean rooms for APIs and adhere to international standards like EU-GMP, WHO-GMP, PMDA, and COFEPRIS. Ami serves as a reliable partner for contract development and manufacturing, offering generic APIs to global pharma companies across more than 60 countries.
AMI Lifesciences

03

arrow
Biotech Showcase
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Vibegron

About the Company :

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

04

Suanfarma

Spain
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSuanfarma, at the Core of a Better Life.

Flag Spain
Digital Content Digital Content

Vibegron

About the Company : Suanfarma founded in 1993, is a B2B life science partner committed to health & innovation by developing, manufacturing, & distributing high-quality APIs for the pharmaceutical indu...

Suanfarma founded in 1993, is a B2B life science partner committed to health & innovation by developing, manufacturing, & distributing high-quality APIs for the pharmaceutical industry innovatively & sustainably. Backed by a robust global network of 12 strategically located local offices, we cater to the needs of over 400 active customers in 70+ countries. At Suanfarma we offer our CDMO capacity for fermentation & chemical synthesis projects, offering a One Stop Shop service with a solid track record, & which allows us to achieve success in the development, scaling, manufacturing, & commercialization of an API, either innovative or generic.
Suanfarma

05

Medichem S.A

Spain
arrow
Biotech Showcase
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMedichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.

Flag Spain
Digital Content Digital Content

Vibegron

About the Company : Medichem is an indepently-owned company based in Barcelona. Founded in 1972 and with more than 45 years, Medichem has been engaged in the process development and manufacture of Act...

Medichem is an indepently-owned company based in Barcelona. Founded in 1972 and with more than 45 years, Medichem has been engaged in the process development and manufacture of Active Pharmaceutical Ingredients (APIs), including Highly Potent. In 2016, Medichem merged with Combino Pharm, which is devoted to the development and manufacture (licensing) of Finished Dosage Forms. With this merger, Medichem has become a vertically integrated pharmaceutical company which can offer a complete range of products and services for the pharmaceutical industry with the highest standards of quality, operational excellence and environment respect.
Medichem

06

Biotech Showcase
Not Confirmed
arrow
arrow
Biotech Showcase
Not Confirmed

Vibegron

About the Company : Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients a...

Beijing Sjar Technology Development Co., Ltd. founded in 2014, it is a high-tech enterprise which specialized in the research and development of active pharmaceutical ingredients and their intermediates, electronic chemical materials and intermediates, large-scale production, sales and services, and provide customized synthetic services according to customer requirements. Sjar-Tech locates in Beijing Economic and Technological Development Zone, has its own R&D and development laboratory. Sjar-Tech has set up a R&D team with rich experience and strong technical strength, most of the practitioners have more than ten years' experience.
blank

07

Biotech Showcase
Not Confirmed
arrow
arrow
Biotech Showcase
Not Confirmed

Vibegron

About the Company : Hope Chem is dedicated to manufacturing, marketing, and CMO service of Active Pharmaceutical Ingredients (APIs), Intermediates, and Specialty Chemicals since the year 2010. Current...

Hope Chem is dedicated to manufacturing, marketing, and CMO service of Active Pharmaceutical Ingredients (APIs), Intermediates, and Specialty Chemicals since the year 2010. Currently, they have exclusive partnerships with multiple, state-of-the-art and GMP-compliant manufacturers in China and abroad to service our esteemed partners for competitive, long-term & stable supplies. The main products are APIs and intermediates of antiviral drug substances and anti-inflammatory, analgesic, and non-steroidal pharmaceuticals.
blank

08

Symed Labs

India
Biotech Showcase
Not Confirmed
arrow

Symed Labs

India
arrow
Biotech Showcase
Not Confirmed

Vibegron

About the Company : Symed Labs Ltd is a leading Hyderabad based manufacturer of Active Pharmaceutical Ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry for chemist...

Symed Labs Ltd is a leading Hyderabad based manufacturer of Active Pharmaceutical Ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry for chemistry related services. We are more than 300 employees strong and our core competence is in the application of strong process chemistry to manufacturing in a regulatory environment. For the past 15 years, Symed has been at the forefront of facilitating and accelerating drug development (and GMP manufacturing) of APIs. The company's technical and scientific teams provide reliable solutions and services to the global pharmaceutical industry.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1668364200,"product":"VIBEGRON (FCI 3558 STAGE-III)","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PAR KAMANI JUNCTION, LBS MARG,","city":"KURLA, MUMBAI","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"NEW YORK - JOHN F. K","customer":"J-STAR RESEARCH","customerCountry":"UNITED STATES","quantity":"0.15","actualQuantity":"150","unit":"GMS","unitRateFc":"1.5","totalValueFC":"220.6","currency":"USD","unitRateINR":120,"date":"14-Nov-2022","totalValueINR":"18000","totalValueInUsd":"220.6","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"5448516","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PAR KAMANI JUNCTION, LBS MARG,, KURLA, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1712514600,"product":"PHARMACEUTICAL RAW MATERIAL AS PERPO NO. F\/53069-24 VIBEGRON","address":"2 FLR.PRESTIGE PLAZA","city":"AKOTA BARODA","supplier":"AMI LIFESCIENCES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"EGYPT","customerCountry":"EGYPT","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"8000","totalValueFC":"79003.6","currency":"USD","unitRateINR":659738.07000000007,"date":"08-Apr-2024","totalValueINR":"6597380.7","totalValueInUsd":"79003.6","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"8987452","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"2 FLR.PRESTIGE PLAZA, AKOTA BARODA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1712860200,"product":"VIBEGRON - FCI 3558 STAGE-III","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK","city":"KURLA, MUMBAI","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"SINGAPORE","customer":"SUMITOMO PHARMA AMERICA, INC","customerCountry":"SINGAPORE","quantity":"1072.94","actualQuantity":"1072.94","unit":"KGS","unitRateFc":"3987","totalValueFC":"4231333.4","currency":"USD","unitRateINR":329326.19997390348,"date":"12-Apr-2024","totalValueINR":"353347253","totalValueInUsd":"4231333.4","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"9072223","productDescription":"Intermediate","marketType":"LESS REGULATED MARKET","country":"SINGAPORE","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK, KURLA, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1714674600,"product":"PHARMACEUTICAL RAW MATERIAL AS PERPO NO. F\/53069-24 VIBEGRON","address":"2 FLR.PRESTIGE PLAZA","city":"AKOTA BARODA","supplier":"AMI LIFESCIENCES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"EL QAHIRA (= CAIRO)","customer":"EGYPT","customerCountry":"EGYPT","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"7951.1","totalValueFC":"79078","currency":"USD","unitRateINR":659148,"date":"03-May-2024","totalValueINR":"6591480","totalValueInUsd":"79078","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"9607683","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"2 FLR.PRESTIGE PLAZA, AKOTA BARODA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1715193000,"product":"PHARMACEUTICAL RAW MATERIAL AS PERPO NO.PRB-0156\/022024 VIBEGRON","address":"2 FLR.PRESTIGE PLAZA","city":"AKOTA BARODA","supplier":"AMI LIFESCIENCES PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"DHAKA BANK PLC","customerCountry":"BANGLADESH","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"11000","totalValueFC":"21701.9","currency":"USD","unitRateINR":904470,"date":"09-May-2024","totalValueINR":"1808940","totalValueInUsd":"21701.9","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"9758900","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"2 FLR.PRESTIGE PLAZA, AKOTA BARODA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1729621800,"product":"PHARMACEUTICAL RAW MATERIAL 1 KGS . MFG. DT. JUN 2024 RETEST DATE .MAY 2025 DESTINATION:COLOMBIA VIBEGRON IH","address":"B-321, ANTOPHILL WAREHOUSING,VIDYA","city":"MUMBAI,MAHARASHTRA","supplier":"CREST REMEDIES LLP","supplierCountry":"INDIA","foreign_port":"BOGOTA","customer":"TO ,","customerCountry":"COLOMBIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"15600","totalValueFC":"15446.5","currency":"USD","unitRateINR":1297920,"date":"23-Oct-2024","totalValueINR":"1297920","totalValueInUsd":"15446.5","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"5056556","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"COLOMBIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"B-321, ANTOPHILL WAREHOUSING,VIDYA, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1676053800,"product":"FREE OF COST-VIBEGRON-(6S)-N-[[(2S,5R)-5-[(R)-HYDROXY(PHENYL)METHYL]PYRROLIDIN-2-YL]METHYL]PHENYL]-4-OXO-7,8-DIHYDRO-6H-","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PAR KAMANI JUNCTION, LBS MARG,","city":"KURLA, MUMBAI","supplier":"UROVANT SCIENCES","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"PIRAMAL PHARMA SOLUTIONS","customerCountry":"INDIA","quantity":"255.00","actualQuantity":"255","unit":"KGS","unitRateFc":"5000","totalValueFC":"1277469.7","currency":"USD","unitRateINR":"413750","date":"11-Feb-2023","totalValueINR":"105506250","totalValueInUsd":"1277469.7","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"4604467","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PAR KAMANI JUNCTION, LBS MARG,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1685730600,"product":"FREE OF CHARGE-VIBEGRON-(6S)[4[[(2S,5R)5[(R)HYDROXY(PHENYL)METHYL]PYRROLIDIN2YL]METHYL]PHENYL]-4-OXO-7,8DIHYDRO-6H-PYRRO","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PAR KAMANI JUNCTION, LBS MARG,","city":"KURLA, MUMBAI","supplier":"UROVANT SCIENCES","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"PIRAMAL PHARMA SOLUTIONS","customerCountry":"INDIA","quantity":"255.00","actualQuantity":"255","unit":"KGS","unitRateFc":"5000","totalValueFC":"1293671.6","currency":"USD","unitRateINR":"416999.8","date":"03-Jun-2023","totalValueINR":"106334999.8","totalValueInUsd":"1293671.6","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PAR KAMANI JUNCTION, LBS MARG,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1713465000,"product":"VIBEGRON API ( LOT NO:2402003,2402004 (6S)-N-4-(2S,5R)-5-(R)-HYDROXY(PHENYL)METHYLPYRROLIDIN-2-YL ) (AS PER INV)","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK","city":"KURLA, MUMBAI","supplier":"UROVANT SCIENCES GMBH","supplierCountry":"JAPAN","foreign_port":"OSAKA - KANSAI INT\\'L","customer":"PIRAMAL PHARMA SOLUTIONS","customerCountry":"INDIA","quantity":"1281.50","actualQuantity":"1281.5","unit":"KGS","unitRateFc":"2151","totalValueFC":"2785973.6","currency":"USD","unitRateINR":"181544.4","date":"19-Apr-2024","totalValueINR":"232649148.6","totalValueInUsd":"2785973.6","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"3096755","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"OSAKA - KANSAI INT\\'L","supplierAddress":"GOTTHARDSTRASSE 3,6300 ZUG,, SWITZERLAND","customerAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK"}]
14-Nov-2022
23-Oct-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Obgemsa (vibegron) is a beta-3 adrenergic agonist, small molecule, which is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency in adults.


Lead Product(s): Vibegron

Therapeutic Area: Urology Brand Name: Obgemsa

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 28, 2024

blank

01

Pierre Fabre

France
arrow
BIO Partnering at JPM
Not Confirmed

Pierre Fabre

France
arrow
BIO Partnering at JPM
Not Confirmed

Details : Obgemsa (vibegron) is a beta-3 adrenergic agonist, small molecule, which is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency in adults.

Brand Name : Obgemsa

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 28, 2024

blank

Details:

Gemtesa (vibegron) is a beta-3 adrenergic receptor agonist for treating male overactive bladder (OAB) with benign prostatic hyperplasia.


Lead Product(s): Vibegron

Therapeutic Area: Urology Brand Name: Gemtesa

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 13, 2024

blank

02

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Gemtesa (vibegron) is a beta-3 adrenergic receptor agonist for treating male overactive bladder (OAB) with benign prostatic hyperplasia.

Brand Name : Gemtesa

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 13, 2024

blank

Details:

Obgemsa (vibegron) is a beta-3 adrenergic agonist indicated for treating overactive bladder symptoms, including urge incontinence and urinary urgency.


Lead Product(s): Vibegron

Therapeutic Area: Urology Brand Name: Obgemsa

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 26, 2024

blank

03

Pierre Fabre

France
arrow
BIO Partnering at JPM
Not Confirmed

Pierre Fabre

France
arrow
BIO Partnering at JPM
Not Confirmed

Details : Obgemsa (vibegron) is a beta-3 adrenergic agonist indicated for treating overactive bladder symptoms, including urge incontinence and urinary urgency.

Brand Name : Obgemsa

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 26, 2024

blank

Details:

Gemtesa (vibegron) is a once-daily beta-3 adrenergic receptor (β3) agonist, is currently under investigation for the treatment of men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia.


Lead Product(s): Vibegron

Therapeutic Area: Urology Brand Name: Gemtesa

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 11, 2023

blank

04

Sumitomo

Japan
arrow
BIO Partnering at JPM
Not Confirmed

Sumitomo

Japan
arrow
BIO Partnering at JPM
Not Confirmed

Details : Gemtesa (vibegron) is a once-daily beta-3 adrenergic receptor (β3) agonist, is currently under investigation for the treatment of men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia.

Brand Name : Gemtesa

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 11, 2023

blank

Details:

KYORIN will grant Sumitomo Pharma the exclusive rights to develop, manufacture, and commercialize the therapeutic agent for OAB called Vibegron in in Taiwan and Other Asian Countries, and Sumitomo Pharma will develop, manufacture, and commercialize the Compound.


Lead Product(s): Vibegron

Therapeutic Area: Urology Brand Name: Gemtesa

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Sumitomo

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 06, 2023

blank

05

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : KYORIN will grant Sumitomo Pharma the exclusive rights to develop, manufacture, and commercialize the therapeutic agent for OAB called Vibegron in in Taiwan and Other Asian Countries, and Sumitomo Pharma will develop, manufacture, and commercialize the C...

Brand Name : Gemtesa

Molecule Type : Small molecule

Upfront Cash : Undisclosed

March 06, 2023

blank

Details:

GEMTESA (vibegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.


Lead Product(s): Vibegron

Therapeutic Area: Urology Brand Name: Gemtesa

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 27, 2022

blank

06

Urovant Sciences

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Urovant Sciences

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Details : GEMTESA (vibegron) is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.

Brand Name : Gemtesa

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 27, 2022

blank

Details:

Urovant Sciences and Pierre Fabre will share responsibility for Gemtesa (vibegron), clinical trials in the pediatric populations in Europe. As part of the transaction, Urovant Sciences will also provide manufacturing services to Pierre Fabre.


Lead Product(s): Vibegron

Therapeutic Area: Urology Brand Name: Gemtesa

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Pierre Fabre

Deal Size: $75.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement July 05, 2022

blank

07

Urovant Sciences

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Urovant Sciences

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Details : Urovant Sciences and Pierre Fabre will share responsibility for Gemtesa (vibegron), clinical trials in the pediatric populations in Europe. As part of the transaction, Urovant Sciences will also provide manufacturing services to Pierre Fabre.

Brand Name : Gemtesa

Molecule Type : Small molecule

Upfront Cash : Undisclosed

July 05, 2022

blank

Details:

In a subgroup analysis of adults, 65 years old or above with overactive bladder, treatment with GEMTESA (Vibegron) was safe and well-tolerated. Treatment with GEMTESA was associated with sustained reductions from baseline in average daily micturition.


Lead Product(s): Vibegron

Therapeutic Area: Urology Brand Name: Gemtesa

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 15, 2022

blank

08

Urovant Sciences

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Urovant Sciences

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Details : In a subgroup analysis of adults, 65 years old or above with overactive bladder, treatment with GEMTESA (Vibegron) was safe and well-tolerated. Treatment with GEMTESA was associated with sustained reductions from baseline in average daily micturition.

Brand Name : Gemtesa

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 15, 2022

blank

Details:

Post-hoc analysis indicates significant reductions in urgency episodes and micturitions in patients treated with GEMTESA vs. placebo in both types of overactive bladder (OAB).


Lead Product(s): Vibegron

Therapeutic Area: Urology Brand Name: Gemtesa

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 19, 2022

blank

09

Urovant Sciences

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Urovant Sciences

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Details : Post-hoc analysis indicates significant reductions in urgency episodes and micturitions in patients treated with GEMTESA vs. placebo in both types of overactive bladder (OAB).

Brand Name : Gemtesa

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 19, 2022

blank

Details:

The Therapeutics and Clinical Risk Management paper points out that in international phase 3 EMPOWUR trial, treatment with GEMTESA was associated with significant improvements compared with placebo.


Lead Product(s): Vibegron

Therapeutic Area: Urology Brand Name: Gemtesa

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 22, 2022

blank

10

Urovant Sciences

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Urovant Sciences

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Details : The Therapeutics and Clinical Risk Management paper points out that in international phase 3 EMPOWUR trial, treatment with GEMTESA was associated with significant improvements compared with placebo.

Brand Name : Gemtesa

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 22, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

read-more
read-more

01

Duphat
Not Confirmed
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPorton Pharma Solutions: Value creation via innovation & discovery through technical platforms.

CAS Number : 1628836-08-7

End Use API : Vibegron

About The Company : Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & ope...

Porton Company Banner

02

Duphat
Not Confirmed
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPorton Pharma Solutions: Value creation via innovation & discovery through technical platforms.

CAS Number : 1190392-22-3

End Use API : Vibegron

About The Company : Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & ope...

Porton Company Banner

03

Duphat
Not Confirmed
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPorton Pharma Solutions: Value creation via innovation & discovery through technical platforms.

CAS Number : 1421271-01-3

End Use API : Vibegron

About The Company : Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & ope...

Porton Company Banner

04

Duphat
Not Confirmed
arrow
Duphat
Not Confirmed
arrow

CAS Number : 1190392-22-3

End Use API : Vibegron

About The Company : Accel Pharmtech, LLC is one of the world’s leading pharmaceutical companies that manufactures and provides their clients and partners with cataloged chemicals...

blank

05

Duphat
Not Confirmed
arrow
Duphat
Not Confirmed
arrow

CAS Number : 1190392-22-3

End Use API : Vibegron

About The Company : Hangzhou Hairui Chemical Co., Ltd. is located in the Zhongheng Century Science and Technology Park in Hangzhou, Zhejiang. It is an excellent manufacturer of org...

blank

06

JieJie Group

China
Duphat
Not Confirmed
arrow

JieJie Group

China
Duphat
Not Confirmed
arrow

CAS Number : 1628836-08-7

End Use API : Vibegron

About The Company : JieJie Group Co., Ltd. is a pharmaceutical and chemical enterprise for research and production, it was built in 2009. Our core business is custom synthesis and ...

blank

07

Duphat
Not Confirmed
arrow
Duphat
Not Confirmed
arrow

CAS Number : 1190392-22-3

End Use API : Vibegron

About The Company : Jinan Shangbo Pharmaceutical Co., Ltd is a high-tech enterprise that specializes in the R&D, production, and sales of pharmaceutical intermediates and fine chem...

blank

08

Duphat
Not Confirmed
arrow
Duphat
Not Confirmed
arrow

CAS Number : 1628836-08-7

End Use API : Vibegron

About The Company : Jinan Shangbo Pharmaceutical Co., Ltd is a high-tech enterprise that specializes in the R&D, production, and sales of pharmaceutical intermediates and fine chem...

blank

09

Duphat
Not Confirmed
arrow
Duphat
Not Confirmed
arrow

CAS Number : 1190392-22-3

End Use API : Vibegron

About The Company : Taizhou Volsen Chemical Co., Ltd. is professional in R&D, producing and marketing Pharmaceutical raw materials, pharmaceutical intermediates in China. VOLSEN co...

blank

10

Duphat
Not Confirmed
arrow
Duphat
Not Confirmed
arrow

CAS Number : 1190392-22-3

End Use API : Vibegron

About The Company : Zhejiang Eazy Pharmchem Co., Ltd. which was established since from 1998, has been actively developing specialty products for APIs, Intermediates, and Fine chemi...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Urovant Sciences

Switzerland
Duphat
Not Confirmed
arrow

Urovant Sciences

Switzerland
arrow
Duphat
Not Confirmed

VIBEGRON

Brand Name : GEMTESA

Dosage Form : TABLET;ORAL

Dosage Strength : 75MG

Packaging :

Approval Date : 2020-12-23

Application Number : 213006

Regulatory Info : RX

Registration Country : USA

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

UROVANT

Switzerland
Duphat
Not Confirmed
arrow

UROVANT

Switzerland
arrow
Duphat
Not Confirmed

VIBEGRON

Brand Name : GEMTESA

Dosage Form : TABLET;ORAL

Dosage Strength : 75MG

Approval Date : 2020-12-23

Application Number : 213006

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
PharmaCompass
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
Duphat
Not Confirmed

UROVANT

Switzerland
arrow
Duphat
Not Confirmed

VIBEGRON

US Patent Number : 12102638

Drug Substance Claim :

Drug Product Claim :

Application Number : 213006

Patent Use Code : U-3045

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2040-03-22

blank

02

arrow
Duphat
Not Confirmed

UROVANT

Switzerland
arrow
Duphat
Not Confirmed

VIBEGRON

US Patent Number : 8653260

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 213006

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-04-02

blank

03

arrow
Duphat
Not Confirmed

UROVANT

Switzerland
arrow
Duphat
Not Confirmed

VIBEGRON

US Patent Number : 8247415

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 213006

Patent Use Code : U-3045

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-12-01

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Vibegron Manufacturers

A Vibegron manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vibegron, including repackagers and relabelers. The FDA regulates Vibegron manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vibegron API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Vibegron manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Vibegron Suppliers

A Vibegron supplier is an individual or a company that provides Vibegron active pharmaceutical ingredient (API) or Vibegron finished formulations upon request. The Vibegron suppliers may include Vibegron API manufacturers, exporters, distributors and traders.

click here to find a list of Vibegron suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Vibegron USDMF

A Vibegron DMF (Drug Master File) is a document detailing the whole manufacturing process of Vibegron active pharmaceutical ingredient (API) in detail. Different forms of Vibegron DMFs exist exist since differing nations have different regulations, such as Vibegron USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Vibegron DMF submitted to regulatory agencies in the US is known as a USDMF. Vibegron USDMF includes data on Vibegron's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Vibegron USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Vibegron suppliers with USDMF on PharmaCompass.

Vibegron KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Vibegron Drug Master File in Korea (Vibegron KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Vibegron. The MFDS reviews the Vibegron KDMF as part of the drug registration process and uses the information provided in the Vibegron KDMF to evaluate the safety and efficacy of the drug.

After submitting a Vibegron KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Vibegron API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Vibegron suppliers with KDMF on PharmaCompass.

Vibegron NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Vibegron as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Vibegron API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Vibegron as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Vibegron and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Vibegron NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Vibegron suppliers with NDC on PharmaCompass.

Vibegron GMP

Vibegron Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Vibegron GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vibegron GMP manufacturer or Vibegron GMP API supplier for your needs.

Vibegron CoA

A Vibegron CoA (Certificate of Analysis) is a formal document that attests to Vibegron's compliance with Vibegron specifications and serves as a tool for batch-level quality control.

Vibegron CoA mostly includes findings from lab analyses of a specific batch. For each Vibegron CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Vibegron may be tested according to a variety of international standards, such as European Pharmacopoeia (Vibegron EP), Vibegron JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vibegron USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty